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Abstract
Background: Low avidity of antibodies against viral, bacterial and parasitic agents has been used for differential
diagnosis of acute versus recent/past infections. The low-avidity antibodies may however, persist for a longer
period in some individuals.
Findings: We studied the association of human papillomavirus (HPV) type 16 antibody avidity with seroprevalence
to HPV types 6/11/18/31/33/45. Antibody avidity was analysed for 365 HPV16 seropositive pregnant Finnish and
Ugandan women using a modified ELISA.
Low avidity of HPV16 antibodies was found in 15% of Finnish and 26% of Ugandan women. Ugandan women
with low-avidity HPV16 antibodies had an increased risk estimate for HPV6/11 (odds ratio, OR 2.9; 95%CI 1.01-8.4)
seropositivity but not to high-risk HPV types 18/31/33/45.
Conclusion: Association of the low avidity HPV16 antibody “phenotype” with possible susceptibility to infections
with other HPV types warrants investigation.
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Background
Persistent infections with high-risk human papilloma-
virus (hrHPV) type 16 cause half of cervical cancer
(CxCa) morbidity/mortality [1,2]. Infections with multi-
ple hrHPVs further increase the CxCa risk, and promote
progression of cervical intraepithelial neoplasia (CIN)
[3,4]. Vaccines against HPV16 and HPV18 (HPV16/18)
have high protective efficacy against infections with the
vaccine and some non-vaccine HPV types (31/45) and
associated CIN [5-7]. Various other non-vaccine HPV
types 33/35/52/58 are, also however, relatively prevalent
in Finland and Uganda [8-11].
HPV16 causes genital infections. Following the infec-
tion, development of antibody response takes from 6 to
18 months [12,13]. During this time, HPV is resolved
through T helper cell activation of cytotoxic T cells and
B cells to produce neutralizing IgG antibodies [12].
Immune response eliminates HPV in 90% of infected
women [4].
Maturation of the IgG antibody avidity takes approxi-
mately 6 months [14-16]. This is used in the distinction
of acute and recent/past infections with, e.g., toxoplas-
mosis, rubella, and parvovirus [17-20]. On the other
hand, low-avidity antibodies have been found (outside
the 6 months period) in chronic infections, e.g., cytome-
galovirus (CMV) and HPV16 [21-23].
We evaluated whether presence of low-avidity of
HPV16 antibodies is associated with an increased risk of
prevalence for other HPV types.
Material and methods
Participants
A total of 4748 pregnant Finnish (2784) and Ugandan
(1964) women participated in an epidemiological study
[10]. In Finland, all pregnant women donate serum sam-
ples to Finnish Maternity Cohort (FMC) for the screen-
ing of congenital infections and consent to further
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serological use of the samples for health-related research
[10,24]. In Uganda all participating women consented
for the use of the samples to serological HPV and other
sexually transmitted infections research [10]. The study
was approved by the institutional review boards at the
National Institute for Health and Welfare (THL), Fin-
land; Uganda Virus Research Institute; St Raphael of St
Francis Hospital Nsambya, and Uganda National Coun-
cil of Science and Technology.
Laboratory analysis
Chlamydia trachomatis and HIV antibodies, and serum
cotinine (current smoking > 20 ng/ml) were analysed by
ELISA as described [10]. Standard ELISA for HPV6/11/
16/18/31/33/45 antibodies was used [10,24-27], with
modifications [17-19] for HPV16 antibody avidity analy-
sis. Briefly, Nunc™ micro plates were coated with
HPV16 VLPs (kindly provided by Kathrin Jansen, Merck
Research Labs, Philadelphia, PA) by overnight incuba-
tion at 4°C. Samples were serially diluted: 1:1, 1:4, 1:16,
1:64, 1:256 in phosphate-buffered saline (PBS) with 10%
fetal bovine serum (blocking buffer, BB). After blocking
the plate, 50 ul of diluted samples were added to wells
A-D (1:4,1:16,1:64,1:256) and wells E-H
(1:1,1:4,1:16,1:64). To columns 1, 2 and 3, blank, low
and high avidity controls were added and incubated
overnight at 4°C [28]. Wells A-D were washed 3 times
with 200 ul of PBS/0.05% Tween 20 (PBS + T), and
wells E-H were washed with 6M urea (Promega, Biofel-
lows, Finland) in PBS. Each wash was for 5 min. All
wells were again washed two times with PBS + T, and
wells E-H, treated with the 6M urea, were washed three
extra times to remove excess urea. The primary and sec-
ondary antibodies were incubated for 90 and 60 min. An
ABTS-substrate was added and the reaction stopped
after 40 min. Optical densities (OD) of each control and
individual samples were plotted: Curve 1: OD from urea
wash and Curve 2: OD from PBS + T wash. Distance
between the curves at OD 0.2 (IgG threshold) was mea-
sured and matched with corresponding avidity index
[17-20]. Cut-off for low-avidity (30%) was calculated
from mean + 3 SD of low-avidity controls added on
each of the 40 plates, according to standard procedures
[18-20]. The low avidity controls were identified by
repeated measurements from sera obtained one month
post third dose in conjunction of an HPV vaccination
study.
Statistical analysis
Logistic regression was used to calculate the relative risk
(odds ratio, OR, with 95% confidence intervals, 95%CI)
of being HPV6/11/18/31/33/45 seropositive associated
with low avidity HPV16 antibodies. Single HPV16 sero-
positives were the reference group. Adjustment was
stepwise for age, Chlamydia trachomatis and HIV anti-
bodies, and cotinine. Statistical analyses were done using
Stata 8 (College Station, TX).
Results and Discussion
Overall, HPV16 seroprevelances were equal (21%) in
both countries [10]. Altogether 365 of the 994 originally
HPV16 seropositive women [10] were randomly
selected. Majority (248) were Finns (mean age of 22
years), 117 were Ugandans (mean age 23 years). Among
the Finns 113 had HPV16 antibodies only, 36 had
HPV16+ HPV6 or HPV11 antibodies, 59 had HPV16+
HPV31 or HPV33 antibodies, and 40 had HPV16+
HPV18 or HPV45 antibodies. Among the Ugandans 45
had HPV16 antibodies only, 32 had HPV16+ HPV6 or
HPV11 antibodies, 24 had HPV16+ HPV31 or HPV33
antibodies, and 16 had HPV16+ HPV18 or HPV45 anti-
bodies (Table 1).
Overall, the prevalence of low-avidity HPV16 antibo-
dies was 15% (38/248) among the Finns and 26% (30/
117) among the Ugandans (p < 0.0001). There was no
statistically significant correlation (Pearson correlation
co-efficient 0.07, p = 0.15) between HPV16 antibody
avidity and age (Figure 1). The seroprevalences of HIV,
C. trachomatis, and smoking were 0%, 25% and 23%
(16/69, cotinine data available) among the Finns and 9%,
27% and 2% (2/111, questionnaire data available) among
the Ugandans.
HPV6/11 seropositivity was increased in women who
had low-avidity HPV16 antibodies (crude OR 2.4, 95%CI
1.3-4.6). After stratification by country and adjustment,
increased risk for being HPV6/11 seropositive was
found only among the Ugandans (adjusted OR 2.9, 95%
CI 1.01-8.4). Estimates on the association of low-avidity
with seropositivity for other hrHPVs were not different
from unity (Table 2).
HPV16 seropositivity is associated with increased risk
of acquiring other HPVs [10,26,29]. The prevalence of
low-avidity of HPV16 antibodies was 15% and 26%
among pregnant Finnish and Ugandan women, respec-
tively. Sexual risk-taking behavior also predisposes
women to various HPV types earlier in Uganda than in
Finland [10]. Thus, the Ugandans had more time to get
infected with both HPV16 and other HPV infections
than the Finns. There were, however, higher proportions
of HPV16 seropositive Ugandans with low-avidity
HPV16 antibodies and increased risk of HPV6 or 11
prevalence.
Low-avidity antibodies induced by microbial antigens
alone are less variable and less functionally versatile than
those induced with T-cell help [14,30]. In immuno-com-
promized patients low-avidity cytomegalovirus antibodies
can persist for several months [21,22]. Comparable
delayed maturation of HPV16 antibody avidity, probably
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associated with impaired ability to produce high quality
neutralizing antibodies, identified women with increased
risk for HPV6 or HPV11 seropositivity, possibly due to
increased susceptibility. On the other hand, the first evi-
dence from the HPV vaccination studies showed that fol-
lowing HPV vaccination, there was no correlation between
avidity and neutralization capacity of the vaccine induced
antibodies [31]. Why only the lrHPV occurrence was
increased in our study remained unclear.
HPV16 seropositives only were eligible for the study.
Thus, due to moderate sensitivity (75%) of HPV16 serol-
ogy [28] some HPV16 infected women could have been
excluded. Moreover, even if HPV seropositivity is an
indicator of cumulative incidence of HPV infections
Table 1 Association (odds ratio, OR, with 95% confidence interval, CI) of low avidity HPV16 antibodies (ab) with
increased risk of being seropositive for other HPV types among Finnish and Ugandan women
Population Seropositivity Total Prevalence of low ab-avidity (%) Crude OR (95% CI)
Finland (n = 248) HPV16 only 113 19 (7.7%) 1
HPV16 + 6 or 11 36 8 (6.3%) 1.4 (0.6-3.6)
HPV16 + 31 or 33 59 5 (2.5%) 0.5 (0.2-1.3)
HPV16 + 18 or 45 40 6 (2.2%) 0.9 (0.3-2.4)
Uganda (n = 117) HPV16 only 45 9 (7.7%) 1
HPV16 + 6 or 11 32 15 (12.8%) 3.5 (1.3-9.7)
HPV16 + 31 or 33 24 4 (3.4%) 0.8 (0.2-2.9)
HPV16 + 18 or 45 16 2 (1.7%) 0.6 (0.1-4.0)
All (n = 365) HPV16 only 158 28 (7.7%) 1
HPV16 + 6 or 11 68 23 (6.3%) 2.4 (1.3-4.6)
HPV16 + 31 or 33 83 9 (2.5%) 0.6 (0.3-1.3)
HPV16 + 18 or 45 56 8 (2.2%) 0.8 (0.3-1.8)
All = combined data of Finnish and Ugandan women
Cutoff_30% = using low avidity controls mean plus 3 standard deviations
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Figure 1 Correlation between antibody avidity and age (Pearson correlation co-efficient 0.07, p = 0.15).
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[12,25,28] our cross-sectional approach did not reveal
the order of acquiring the various HPV infections.
The association was seen only in the Ugandans, whose
HIV seroprevalence was 9%. Adjusting for HIV, how-
ever, had no effect on the low-avidity associated risk,
antibody avidity is not affected by HIV infection [21,22].
Smoking, which impairs HPV antibody response [27],
might, however, intervene with the development
(maturation) of antibody avidity as the observed associa-
tion almost lost statistical significance after adjusting for
smoking. In conclusion, association of the low avidity
HPV16 antibody “phenotype” with possible susceptibility
to other HPV infections warrants investigation.
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